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Abstract: Expression of the cell adhesion molecule (CAM), Sialyl Lewis X (CD15s) correlates with
cancer metastasis, while expression of E-selectin (CD62E) is stimulated by TNF-α. CD15s/CD62E
interaction plays a key role in the homing process of circulating leukocytes. We investigated the
heterophilic interaction of CD15s and CD62E in brain metastasis-related cancer cell adhesion.
CD15s and CD62E were characterised in human brain endothelium (hCMEC/D3), primary non-small
cell lung cancer (NSCLC) (COR-L105 and A549) and metastatic NSCLC (SEBTA-001 and NCI-H1299)
using immunocytochemistry, Western blotting, flow cytometry and immunohistochemistry in human
brain tissue sections. TNF-α (25 pg/mL) stimulated extracellular expression of CD62E while adhesion
assays, under both static and physiological flow live-cell conditions, explored the effect of CD15s-mAb
immunoblocking on adhesion of cancer cell–brain endothelium. CD15s was faintly expressed on
hCMEC/D3, while high levels were observed on primary NSCLC cells with expression highest on
metastatic NSCLC cells (p < 0.001). CD62E was highly expressed on hCMEC/D3 cells activated
with TNF-α, with lower levels on primary and metastatic NSCLC cells. CD15s and CD62E were
expressed on lung metastatic brain biopsies. CD15s/CD62E interaction was localised at adhesion
sites of cancer cell–brain endothelium. CD15s immunoblocking significantly decreased cancer cell
adhesion to brain endothelium under static and shear stress conditions (p < 0.001), highlighting the
role of CD15s–CD62E interaction in brain metastasis.
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1. Introduction
The process of cancer metastasis from one organ to another involves many stages [1,2]. However,
the mechanisms by which cancer cells adhere to and cross the neurovascular unit and subsequently
colonise the brain tissue are not fully substantiated. CD15s (Sialyl Lewis X) is known to be a marker
associated with neoplastic cells and is a natural E-selectin (CD62E) ligand [3,4]. Some cancer cells use a
similar mechanism to that used by extravasating white blood cells (WBCs) whereby cell surface CD15s
binds with endothelial cell CD62E. This CD15s expression and its role in binding to the brain vascular
endothelium via CD62E may explain why some cancer cells have greater brain metastatic potential
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than others. The molecular mechanisms underlying the complex communication between cancer cells
and brain endothelium during brain metastasis, however, require further elucidation.
1.1. The Role of CD15s in Cancer Metastasis
The tetra-polysaccharide molecule CD15s (SLex), expressed on the terminus of cell surface
glycolipids, acts as a ligand for the selectins CD62E (E-selectin) and CD62P (P-selectin) [5], being
centrally involved with neoplastic cell to vascular endothelial cell adhesion [5–9]. The homing process
of circulating WBCs through tethering and rolling is initially facilitated via CD15s/CD62E heterophilic
binding at injury sites [10,11]. Moreover, metastatic colon adenocarcinoma cells have also been shown
to adhere to human umbilical vein endothelial cell (HUVEC) through CD15s/CD62E interaction [9].
An additional link between CD15s and malignancy was made on both human non-small cell lung
cancer (NSCLC) and human primary liver cancer (PLC) in tissue sections [12] while CD15s has also
been reported to be expressed on 51% of advanced primary gastric cancer and metastatic lymph nodes
and on 60% of primary gastric cancer patients [13]. CD15s has also been utilized as an early diagnostic
maker for cervical cancer [14]. The expression of CD15s in brain metastases has, however, hitherto been
under-investigated. Having recently reported CD15s overexpression to be correlated with cell cycle
arrest at G1 phase in both glioblastoma (GBM) cells and brain metastatic cells from lung cancer [15],
we sought to investigate its possible involvement in the initial stages of brain metastasis.
1.2. Role of CD62E (E-Selectin) in Cancer Metastasis
The glycoprotein CD62E, a cell adhesion molecule (CAM), expressed on brain endothelium [16]
following stimulation with tumour necrosis factor alpha (TNF-α) and other cytokines [16,17] can
bind fucosylated and sialylated CD15 on WBCs and neoplastic cells [18,19]. A high affinity between
CD62E and CD15s has also been recognised though crystallographic investigation [19]. Other CD62E
ligands include CD44, CD107a and CD107b [20–22]. In addition, in vivo and in vitro studies have
shown that interactions between CD62P/CD62E and various glycoconjugates mediate the WBC
tethering process during inflammation [23] while the role of CD62E/CD15s interaction in endothelial
binding of circulating cancer cells (CCCs) during the metastatic cascade has been suggested [24].
Indeed, endothelial cell overexpression of CD62E was reported in metastatic lung cancer foci [25]
while in spontaneous murine astrocytoma (SMA-560) model systems transendothelial migration was
reduced by monoclonal antibody blocking of CD62E [26]. Considering the clinical importance of
brain metastasis and the therapeutic challenges, it is crucial to find a way to prevent NSCLC cells
from crossing the blood–brain barrier (BBB). Thus, this study aims to develop our understanding of
the molecular mechanisms underlying metastasis from NSCLC to brain, specifically focussing on the
adhesion of NSCLC cells to brain-derived endothelial cells which compose an important part of the
neuro-vascular unit and constitute the first major obstacle to colonization of the brain by metastatic
cancer cells.
2. Results
2.1. Characterisation of CD15s in Cultured Cells
Localisation and extracellular expression of CD15s were characterised in human brain endothelial
cells as well as primary and metastatic NSCLC cells via immunocytochemistry (ICC), Western blotting
(WB) and flow cytometry (FC) analysis. CD15s was localised and prominently expressed on the
surface of brain metastatic lung cancer cells (SEBTA-001 and NCI-H1299). Lower expression levels
were seen on the surface of brain endothelial cells (hCMEC/D3) and on primary lung cancer cell lines
(COR-L105 and A549) compared with the isotype control (Figure 1A). Semi-qualitative WB analysis
showed intense immunopositive bands in the metastatic cells while less intensity was observed in
primary cancer cells and endothelial cell membrane extracts (Figure 1B). Qualitative FC analysis
showed highest CD15s positivity was observed in metastatic lung cancer cells, NCI-H1299 (39%) and
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SEBTA-001 (35%), followed by brain endothelial cells (hCMEC/D3) (25%) and primary lung cancer
cell lines (COR-L105 (21%) and A549 (18%)) (Figure 1C,D). Note that, while Western blot data suggest
COR-L105 has high CD15s expression, ICC and FC results did not correlate, showing relatively low
expression of this epitope. This probably reflects the different antibodies used in the WB and ICC/FC,
as well as the techniques to quantity the expression level.
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was used as a nuclear counterstain. Scale bar = 20 µm; (B) Western blot analysis of CD15s of proteins 
from the cell lines showed highest CD15s expression in NCI-H1299 and SEBTA-001 followed by 
hCMEC/D3, COR-L105 and A549. Cyclophilin A was used as a protein loading control; (C) 
representative flow cytometric histograms (Green: control, purple: hCMEC/D3, black: NCI-H1299, 
red: SEBTA-001, blue COR-L105 and yellow: A549); (D) quantitative flow cytometric analysis of 
CD15s expression on hCMEC/D3, NCI-H1299, SEBTA-001, COR-L105 and A549. CD15s was 
overexpressed in NCI-H1299 and SEBTA-001 with less expression in hCMEC/D3, COR-L105 and 
A549. n = 3, *** p < 0.001 and ** p < 0.01. Data is expressed as ±SE.  
2.2. The Absence of CD62E Reduced Cancer Cell–Brain Endothelium Adhesion  
To explore the role of CD62E in adhesion of NSCLC cell to brain endothelium, we conducted 
qualitative and quantitative adhesion assays under static conditions. CD62E expression was first 
activated by TNF-α (25 pg/mL). Green fluorescently tagged NSCLC cells were then applied onto 
activated and non-activated brain endothelial cells. Findings showed that absence of CD62E 
significantly reduced the adhesion of all cancer cells (p < 0.001) (Figure 2) compared to the high 
Figure 1. Expression of CD15s in brain endothelial and lung cancer cell lines: (A) Representative ICC
images showing CD15s in hCMEC/D3, NCI-H1299, SEBTA-001, A549 and COR-L105. Hoechst blue was
used as a nuclear counterstain. Scale bar = 20 µm; (B) Western blot analysis of CD15s of proteins from
the cell lines showed highest CD15s expression in NCI-H1299 and SEBTA-001 followed by hCMEC/D3,
COR-L105 and A549. Cyclophilin A was used as a protein loading control; (C) representative flow
cytometric histograms (Green: control, purple: hCMEC/D3, black: NCI-H1299, red: SEBTA-001,
blue COR-L105 and yellow: A549); (D) quantitative flow cytometric analysis of CD15s expression on
hCMEC/D3, NCI-H1299, SEBTA-001, COR-L105 and A549. CD15s was overexpressed in NCI-H1299
and SEBTA-001 with less expression in hCMEC/D3, COR-L105 and A549. n = 3, *** p < 0.001 and
** p < 0.01. Data is expressed as ±SE.
2.2. The Absence of CD62E Reduced Cancer Cell–Brain Endothelium Adhesion
To explore the role of CD62E in adhesion of NSCLC cell to brain endothelium, we conducted
qualitative and quantitative adhesion assays under static conditions. CD62E expression was first
activated by TNF-α (25 pg/mL). Green fluorescently tagged NSCLC cells were then applied onto
activated and non-activated brain endothelial cells. Findings showed that absence of CD62E
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significantly reduced the adhesion of all cancer cells (p < 0.001) (Figure 2) compared to the high
numbers of adherent cells on activated brain endothelial cells expressing CD62E. These results suggest
that CD62E and TNF-α have a key role in adhesion of NSCLC during seeding into the brain.
Int. J. Mol. Sci. 2017, 18, 1474  4 of 16 
 
ers of adherent cells on activated brain endothelial cells expressing CD62E. These results 
suggest that CD62E and TNF-α have a key role in adhesion of NSCLC duri  seeding into the brain. 
 
Figure 2. The role of CD62E in adhesion of NSCLC cells to brain endothelium: (A) Qualitative adhesion 
of NSCLC cells onto brain endothelium monolayer. Green fluorescently tagged NSCLC cells were 
applied onto the hCMEC/D3 monolayer and incubated for 90 min with and without activation via 
TNF-α. Non-adherent cells were washed and co-cultures were fixed and examined by confocal 
microscopy; (B) quantitative adhesion of NSCLC cells. hCMEC/D3 cells were seeded into 96-well 
plate followed by seeding of green fluorescently tagged NSCLC cells on the hCMEC/D3 monolayer 
and incubated for 90 min incubation. Non-adherent cells were washed out and adherent cells were 
lysed followed by quantification via a microplate reader at 480–520 nm. Results showed a strong 
decrease in adhesion caused by absence of TNF-α (White bar) compared to TNF-α stimuli. n = 3, *** p 
< 0.001 and ** p < 0.01. Scale bar = 20 µm. Data is expressed as ±SE. 
2.3. Immunoblocking of CD15s Reduced Adhesion of Cancer Cell–Brain Endothelium under Static Conditions  
A qualitative adhesion assay under static conditions was performed using a confocal 
microscope and quantitatively using a plate reader to assess the role of CD15s in adhesion. Results 
showed that metastatic cancer cells (NCI-H1299 and SEBTA-001) were more adherent than primary 
lung cancer cell lines (COR-L105 and A549) (Figure 3). Immunoblocking of CD15s significantly (p < 
0.001) reduced adhesion of cancer cells onto an activated brain endothelial cell monolayer. These 
results suggested a correlation between the expression of CD15s and endothelial cell adhesion of 
lung cancer cells (Figure 3A). In addition, mAb-immunoblocking against CD15s reduced the 
adhesion of cancer cells compared to the adhesion ability of cancer cells without mAb-CD15s 
immunoblocking. However, no decrease in adhesion was detected during blocking with 
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Figure 2. The role of CD62E in adhesion of NSCLC cells to brain endothelium: (A) Qualitative
adhesion of NSCLC cells onto brain endothelium monolayer. Green fluorescently tagged NSCLC cells
were applied onto the hCMEC/D3 monolayer and incubated for 90 min with and without activation
via TNF-α. Non-adherent cells were washed and co-cultures were fixed and examined by confocal
microscopy; (B) quantitative adhesion of NSCLC cells. hCMEC/D3 cells were seeded into 96-well plate
followed by seeding of green fluorescently tagged NSCLC cells on the hCMEC/D3 monolayer and
incubated for 90 min incubation. Non-adherent cells were washed out and adherent cells were lysed
followed by quantification via a microplate reader at 480–520 nm. Results showed a strong decrease in
adhesion caused by absence of TNF-α (White bar) compared to TNF-α stimuli. n = 3, *** p < 0.001 and
** p < 0.01. Scale bar = 20 µm. Data is expressed as ±SE.
2.3. Immunoblocking of CD15s Reduced Adhesion of Cancer Cell–Brain Endothelium under Static Conditions
A qualitative adhesion assay under static conditions was performed using a confocal microscope
and quantitatively using a plate reader to assess the role of CD15s in adhesion. Results showed
that metastatic cancer cells (NCI-H1299 and SEBTA-001) were more adherent than primary lung
cancer cell lines (COR-L105 and A549) (Figure 3). Immunoblocking of CD15s significantly (p < 0.001)
reduced adhesion of cancer cells onto an activated brain endothelial cell monolayer. These results
suggested a correlation between the expression of CD15s and endothelial cell adhesion of lung
cancer cells (Figure 3A). In addition, mAb-immunoblocking against CD15s reduced the adhesion of
cancer cells compared to the adhesion ability of cancer cells without mAb-CD15s immunoblocking.
However, no decrease in adhesion was detected during blocking with non-specific isotype (IgM)
monoclonal antibodies. These results confirmed the specificity of mAb-CD15s blocking and validated
the correlation of CD15s and adhesion ability of cancer cells under static conditions (Figure 3B).
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Figure 3. (A) CD15s immunoblocking reduced the adhesion of lung cancer cells under static conditions.
Confocal images (top panel) showing adhesion of green fluorescently labelled NSCLCs on a brain
endothelial cell monolayer (blue) and semi-quantitative analysis of confocal images (lower panel)
showed a significant decrease in adhesion ability of NSCLC cells to adhere to hCMEC/D3 cells.
n = 3, *** p < 0.001 and ** p < 0.01. Scale bar = 20 µm. Data is expressed as ±SE. We used the same
concentration of TNF-α as optimised in a previous study [5] to activate the expression of CD62E on
brain endothelial cells. Brain endothelial cells (hCMEC/D3) were exposed to 25 pg/mL of TNF-α
for 18 h and levels of CD62E were detected using flow cytometry (Data not shown); (B) blocking
with CD15s mAb significantly decreased the adhesion of NSCLC to brain endothelium. Quantitative
adhesion assay of human primary and metastatic lung cancer (NSCLC) cells blocked with CD15s
mAb ( lue bar), non-specific isotype IgM (white bar) to assess the efficiency and specificity of CD15s
mAb-bl cking efficiency and NSCLC cells on a monolayer of hCMEC/D3 (grey bar) as a negative
control. n = 3, *** p < 0.001. Data is expressed as ±SE.
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2.4. CD15s mAb Blocking Decreases Adhesion of NSCLC Cells under Shear Stress Condition
To determine whether CD15s plays a role in adhesion of cancer cells under physiological shear
stress (blood flow conditions), an activated endothelial monolayer was allowed to grow on a Vena8
endothelial+ biochip and green fluorescent tagged NSCLC cells were perfused onto the endothelial
monolayer via a micropump (Cellix, Dublin, Ireland). Live cell microscopy was then conducted to
monitor the effect of CD15s immunoblocking on the adhesion of cancer cells. A highly metastatic lung
to brain cancer cell line (SEBTA-001) was perfused at a rate of 2.5 dyn/cm2 with pre-warmed fresh
EBM + EGM2 medium supplemented with 2% human serum and 25 pg/mL TNF-α. Cell adhesion
was then studied over a 90-min time range. Results showed that SEBTA-001 cells adhered onto the
activated endothelial monolayer where no CD15s immunoblocking was applied. The number of
adherent cells was also seen to increase in a time dependent manner (Figure 4). In parallel, the same
number of SEBTA-001 cells (previously incubated with mAb-CD15s for 10 min) was perfused onto
the activated endothelial monolayer and no adhesion was seen. The cancer cells stayed in suspension
(Figure 4 and supplementary materials). These findings confirmed the key role of CD15s in adhesion
of lung cancer cells to brain endothelial cells under physiological shear stress conditions.
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Figure 4. Immunoblocking with CD15s mAb significantly decreased the adhesion ability of NSCLC
under dynamic conditions (2.5 dyn/cm2). A dynamic cell adhesion assay was carried out on highly
metastatic brain cells (SEBTA-001) using an AxioVert 200 M microscope. (Top panel) Cancer cells were
incubated with isotype control (IgM) or CD15 mAb followed by perfusion of 1 × 106 cancer cells over
a monolayer of hCMEC/D3 cells at 2.5 dyn/cm2 for 90 min. Phase contrast and fluorescent images
were acquired at real time every 10 min with a ×5 objective using Volocity software. Scale bar = 20 µm.
(Lower panel) Results are shown in relative fluorescent units of adherent cancer cells with and without
CD15 mAb for 10, 20, 30, 40, 60 and 90 min time points. * p < 0.05. Data is expressed as ±SE.
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2.5. CD15s Expression Was Localised at the Peripheral Adhesion Sites of Cancer Cell–Brain Endothelium
Results showed a prominent expression of CD15s (red) on the surface of green fluorescently tagged
cancer cells with accumulation on the surrounding outer edges and processes of the adherent cancer
cells (Figure 5A). CD15s and CD62E were both co-localised at the site of NSCLC cell adhesion where
CD15s (red) was seen to be expressed on green-tagged cancer cells and CD62E (purple) observed on
the surface of the activated brain endothelial cells at the site of the adhesion (Figure 5B). These images
assessed the involvement of CD15s–CD62E interaction in adhesion process of NSCLC cells onto
brain endothelium.
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2.6. CD15s Expression in Human Biopsy of Lung to Brain Metastasis
Paraffin embedded formalin fixed tissue sections of human lung to brain metastatic tumour biopsy
and normal brain tissue sections were immunostained for CD15s and CD62E. Results showed that
CD15s was expressed in brain metastatic tumour sections. CD15s positive cells were seen throughout
the tumour core and in the distant local lesions. An area of host tumour interface was seen where CD15s
positive cells were detected within vessels. No CD15s expression was observed in the non-malignant
adjacent host brain tissue and in normal brain tissue section (Figure 6, left panel). In parallel, CD62E
was expressed on the inner lining of brain endothelial cells with no expression seen in normal brain
sections (Figure 6, right panel). These results highlight the importance of CD15s and CD62E in
brain metastasis.
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Figure 6. Representative immunohistochemistry images from one patient with lung–brain metastasis.
(Left panel) CD15s was detected in tumour core and infiltrated into non-neoplastic host brain tissue.
No expression was seen in a normal brain section. (Right panel) CD62E was expressed on the inner
lining of brain endothelial cells with no expression seen in normal brain sections. Images were obtained
using an Ariol microscope (Leica, Wetzlar, Germany) at 20× and 40× magnification. Scale bar = 20 µm.
n = 1.
3. Discussion
Brain metastasis is a complicated, multi-step process, the underlying molecular mechanisms of
which are still not fully understood. Twenty to forty per cent of non-small cell lung cancer (NSCLC)
patients develop brain metastasis at or within a short period of primary tumour diagnosis [27].
Metastasis to the brain requires efficient biological interaction between the metastatic cells and their
vascular microenvironment. Circulating cancer cells have to go through tethering, rolling, adhesion
and transmigration during seeding into the brain. Little, however, is known about the molecular
basis of these interactions, particularly, the adhesion process between cancer cell and brain vascular
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endothelium. CD15s is a tetrasaccharide cell–cell adhesion and cell recognition molecule [28], which
is involved in adhesion of lymphocyte during the homing process [29]. CD15s overexpression was
reported to correlate with distant metastasis in lung cancer patients [30], as well as in colorectal
metastatic cancer [31] and liver metastasis where CD15s inaction with selectins mediates adhesion
of cancer cells onto liver endothelium [32]. In addition, elevated levels of CD15s were revealed to
be associated with metastasis in head and neck cancer [33]. Our study showed that CD15s was
expressed on the cell surface of brain endothelial cells (hCMEC/D3), primary NSCLC cell lines (A549
and COR-L105) while the highest levels of expression were observed on NCI-H1299, derived from a
metastatic NSCLC from cervical lymph node, and SEBTA-001, a metastatic NSCLC obtained from the
brain (Figure 1). These results correlated with the findings of Fukuoka et al. (1998) [30] who revealed
that high CD15s expression was correlated with metastasis in lung carcinoma. Similar findings were
shown by Kadota et al. (1999) [34], suggesting CD15s correlates with distant metastatic lesions in lung
carcinoma. Recently, elevated levels of CD15s were reported to be used as an independent marker to
predict NSCLC patients at the metastatic stage [35], although, little is known about CD15s expression
in CNS malignancies. We recently reported that CD15s overexpression was cell cycle dependent in
high grade glioblastoma cells as well as in metastatic brain tumour cells originating from lung [36].
It has also been shown that brain endothelial cells play a key role in metastasis to the brain [37].
An adult human brain microvascular endothelial cell line (hCMEC/D3) was used in our studies [38].
This brain derived endothelial cell line has been well characterised in an all human in vitro BBB
model [15,39,40]. We previously optimised the concentration of TNF-α (25 pg/mL) needed to trigger
the extracellular expression of CD62E on hCMEC/D3 cells [36]. All studied cells were maintained
in medium supplemented with human serum to avoid any possible functional changes enhanced by
bovine serum [41,42]. Previously, non-CNS endothelial cells such as HUVECs have been used to study
metastasis to the brain [43]. A functional difference however was subsequently noted in adhesion of
leukocytes on brain endothelial cells and adhesion on umbilical vein endothelial cells [44]. The use of
all human, brain-derived cellular models is, therefore, of paramount importance [5,39]. The importance
of CD15s in cell–cell adhesion is due to its propensity to interact with endothelial adhesion molecules
such as E-selectin (CD62E), as in the lymphocyte homing process [45,46]. Interestingly, our findings
showed a correlation between expression of CD15s and adhesion. Less adhesion was seen in primary
lung cancer cells (COR-L105 and A549) compared to highly metastatic cells (NCI-H1299, SEBTA-01
and SEBTA-005) (Figure 2). A significant decrease in NSCLC adhesion was observed by the absence
of CD62E and in turn without TNF-α stimuli (Figure 2). Earlier studies showed the involvement of
CD15s–CD62E interaction in metastasis in different non-CNS cancers and revealed that entrapping the
interaction between CD15s and CD62E largely reduced the adhesion of lung carcinoma, colon cancer
and macrophages to endothelial cells [47]. We found that a significant decrease (p < 0.01) in adhesion of
lung cancer cells was caused by blocking with CD15s monoclonal antibodies (Figure 3). These results
suggest that both CD15s and CD62E play an important role in adhesion of cancer cell onto brain
endothelium under static conditions. We then investigated whether blocking of CD15s reduces the
adhesion of cancer cells under a physiological flow system. We conducted live cell imaging of cell–cell
adhesion under shear stress at a perfusion rate of 2.5 dyn/cm2 and volumetric flow rate of 10 mL/h
resembling that of the blood flow in the human brain microvascular system [48]. Using metastatic
NSCLC cells obtained from brain (SEBTA-001), results showed that blocking with antibodies against
CD15s reduced cell adhesion compared with non-blocked cells (Figure 4). Confocal images revealed
CD15s immunopositive cells surrounding the adherent cells and co-localisation of CD15s/CD62E was
seen at the site of adhesion of metastatic lung cancer cells (SEBTA-001) onto brain endothelial cells
(Figure 5). These findings suggest CD15s and CD62E play a key role in lung cancer cell adhesion.
CD15s was also seen to be expressed in human tissue sections of lung to brain metastasis while, no
CD15s was detected in the normal brain tissue sections (Figure 6). Although little is known regarding
the in vivo and in vitro characterisation of CD15s expression in the human CNS, a single study revealed
that CD15s was not expressed in any type of normal brain cell apart from microglia [49].
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Results from this present study, wherein a specialised in vitro experimental model was used
to investigate cell–cell adhesion of metastatic lung cancer cells to brain endothelial cells provide
supporting the role of CD15s/CD62E interactions in lung to brain metastasis and may serve as
a potential therapeutic target. CD15s and its potential role in the binding of circulating tumour
cells to the brain endothelial cells is quite significant given the fact that this may be a step in the
multi-step metastasis process that could be targetable. Preventing the circulating tumour cells from
the initial binding step offers a novel approach to prevention of brain metastasis in patients diagnosed
with NSCLC.
4. Materials and methods
4.1. Ethics Statement
All cell lines established “in house” were conducted in accordance with the National
Research Ethics Service (NRES) instructions and under Ethics permission 11/SC/0048 (received:
29 August 2016).
4.2. Cell Culture
The human cerebral microvascular endothelial cell line (hCMEC/D3) was donated by Pierre
Olivier Couraud (Institute of Cochin, INSERM, Paris, France) [50]. These cells were cultured in
endothelial basal medium-2 (EBM-2; Lonza, Slough, UK) supplemented with Vascular Endothelial
Growth Factor (VEGF), human Epidermal Growth Factor (hEGF), R3-Insulin-like Growth Factor-1
(R3-IGF-1), Ascorbic Acid, Hydrocortisone, human Fibroblast Growth Factor-Beta (hFGF-β), Heparin
(Lonza, Slough, UK) and 2% human serum (Sigma-Aldrich, Gillingham, UK). Primary NSCLC cell lines
(A549 and COR-L105) were purchased from Sigma-Aldrich (Gillingham, UK); metastatic NSCLC from
cervical lymph nodes (NCI-H1299) from ATCC® and low passage brain-metastatic NSCLC (SEBTA-001)
was established “in house” from biopsies derived from patients with lung–brain secondary tumours.
All NSCLC cells were cultured in Dulbecco’s Modified Eagle Medium supplemented with 2% human
serum (Sigma-Aldrich, Gillingham, UK) and maintained at 5% CO2 and a humidified atmosphere
at 37 ◦C. All cell lines were routinely tested for mycoplasma using the MycoAlert™ (Lonza, Slough,
UK) kit. Cell authentication was also carried out routinely using a microfluidic electrophoresis system
via an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), to analyse STR-PCR
fragments from 10 human genomic loci of human cell lines [50].
4.3. Antibodies
4.3.1. Primary Antibodies
Mouse monoclonal anti-CD15s (KM93) (Millipore, ThermoFisher, East Grinstead, UK) was
used at the following dilutions based on the company’s recommended working range: 1:50
for immunocytochemistry (ICC), 1:50 for Western blot (WB), 1:10 for flow cytometry (FC) and
immuno-blocking and 1:100 for immunohistochemistry (IHC). Mouse monoclonal anti-CD62E
(Sigma-Aldrich, Gillingham, UK) was used at the following dilutions: 1:100 for ICC, 1:25 for FC,
1:200 for WB and 1:200 for IHC. Rabbit polyclonal anti-ABCE1 (Novus Technologies, Singapore,
Singapore) was used as a loading control for WB at 1:500.
4.3.2. Secondary Antibodies
Fluorochrome-conjugated Alexa Fluor-488, Alexa Fluor-568 and Alexa Fluor-647 (Invitrogen,
Carlsbad, CA, USA) was used for ICC and FC at 1:500. Horseradish peroxidase (HRP)-conjugated IgG
(Invitrogen, Carlsbad, CA, USA) was used at 1:2500 for chemiluminescent detection in WB.
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4.3.3. Isotype CONTROLS
To confirm the specificity of primary antibody binding, isotype control antibodies were used (IgG
and IgM) (Invitrogen, Carlsbad, CA, USA) at 1:100 for ICC, 1:10 for FC and 1:10 for immunoblocking
for CD15s. IgG Isotype control antibodies (Invitrogen) at dilutions 1:50 for ICC and 1:10 for flow
cytometry for CD62E controls.
4.4. Immunocytochemistry (ICC)
Cells were seeded onto sterile coverslips at 1 × 105/well and left to incubate overnight at 5%
CO2 and a humidified atmosphere at 37 ◦C. Cells were fixed with 4% Paraformaldehyde (PFA)
(Sigma-Aldrich, Gillingham, UK) followed by three washes with Phosphate buffered saline (PBS)
(Sigma-Aldrich, Gillingham, UK). Cells were then blocked with 10% goat serum (Sigma-Aldrich,
Gillingham, UK), incubated with the primary antibody overnight followed by incubation with
secondary antibody for 45 min. Cells were then counterstained with 1 mg/mL of Hoechst Blue
(Sigma-Aldrich, Gillingham, UK). Coverslips were mounted on slides using Vectashield® (Vector
Laboratories, Burlingame, CA, USA) and viewed using a Zeiss Axio Imager Z1 fluorescence
microscope. Images were captured using Volocity Image Analysis Software (V 5.2, PerkinElmer,
Waltham, MA, USA).
4.5. Flow Cytometry (FC)
Cells were harvested by gentle scraping, blocked with 2% goat serum and probed with
primary antibody for 30 min at 4 ◦C. Isotype antibodies were added to the control wells to ensure
specificity of the primary antibodies. Cells were then washed twice with PBS and incubated
with secondary antibody for 20 min at 4 ◦C. Cells were re-suspended in PBS then transferred to
Fluorescence-activated cell sorting (FACS) tubes (BD Biosciences, BD Biosciences, Oxford, UK).
Propidium iodide (PI) (Sigma-Aldrich, Gillingham, UK) was added to samples for extracellular
antigen detection. Analysis was performed using a four-colour multi-parameter FACS Calibur
(BD Biosciences, Oxford, UK) machine. Each experiment was repeated independently three times in
triplicate. The expression level was assessed by percentage of positive cell population.
4.6. Western Blotting (WB)
Cells were lysed using RIPA buffer (ThermoFisher, East Grinstead, UK) with 1× Halt Protease
Phosphatase Inhibitor Cocktail (ThermoFisher, East Grinstead, UK). Lysate protein concentration
was determined by the Pierce BCA Protein assay (ThermoFisher, East Grinstead, UK). Lysates were
separated by SDS-PAGE and protein loaded onto 1.5 mm thick 10% SDS-Polyacrylamide gels and
run for 90 min at 100 V. Proteins were then transferred to methanol-activated Immun-Blot PVDF
membranes (BioRad, Watford, UK) using the Pierce Power System (ThermoFisher, East Grinstead, UK)
(10 min; 10 Volt; 1.2 Ampere). Membranes were then blocked with 5% milk buffer (Marvel, UK) for 1 h
at room temperature (RT). Incubation with the primary antibody was performed overnight at 4 ◦C.
Membranes were washed 3 times with TBST before staining with the secondary antibody conjugated
to a NIR-dye for 1 h at RT. Prior to scanning, the membranes were washed 3 times with TBST and once
with TBS. Blots were scanned on a Li-cor Odyssey CLx and analysed using ImageStudio V5.2 (Licor,
Lincoln, NE, USA).
4.7. Adhesion Assays
4.7.1. Quantitative Adhesion Assay
Adhesion ability of tumour cell–brain endothelial cell was evaluated using the CytoSelect™
Tumor-Endothelium Adhesion Assay Kit (Cell Biolabs, San Diego, CA, USA). Briefly, 48-well
plate (Corning, Corning, NY, USA) was coated with 10 µg/mL of fibronectin (Sigma-Aldrich,
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Gillingham, UK). Then, 1 × 106 cells/well hCMEC/D3 were seeded and grown to 80% confluency.
To activate the extracellular expression of CD62E, hCMEC/D3 cells were incubated at 25 pg/mL of
TNF-α. In parallel, NSCLC cells were stained with live cell green fluorescent dye (Cyto Tracker™)
(Cell Biolabs, San Diego, CA, USA) for 1 h. Then, 1 × 105 of the stained NSCLC cells were seeded
onto the activated hCMEC/D3 monolayer and the co-culture incubated for 90 min. Non-adherent cells
were washed with pre-warmed PBS and the relative number of adherent cancer cells was evaluated
using a POLARstar™ OPTIMA microplate reader (BMG Labtech, Aylesbury, UK). All experiments
were conducted independently three times in triplicate.
4.7.2. Qualitative Adhesion Assay
hCMEC/D3 cells were seeded on fibronectin coated glass coverslips under the same conditions
that were used in the CytoSelect™ adhesion assay. NSCLC cells were tagged with green fluorescent dye,
seeded onto an activated hCMEC/D3 monolayer and incubated for 90 min. Non-adherent cancer cells
were washed off and cells were fixed with 4% PFA. Semi-quantification of adhesion was assessed using
confocal images and Zeiss ZEN software (Zeiss LSM 510 Meta Axioskop2, Carl Zeiss, Cambridge, UK).
4.8. Viability Assays
To determine the effect of blocking with CD15s-monclonal antibody on cell viability, NSCLC cells
were seeded at 1 × 104 in 96-well plates and incubated in growth medium supplemented with CD15s
monoclonal antibody at a dilution of 1:100. Cell viability was then measured at different time points
using CellTiter 96® Aqueous one solution cell proliferation assay (MTS) (Promega UK, Southampton,
UK). Absorbance was measured at 490 nm using a microplate reader (BMG Labtech, Aylesbury, UK).
4.9. Cancer Cell Adhesion under Shear Stress and Live Cell Imaging Microscopy
To assess the adhesion of cancer cell–brain endothelium under shear stress, a Vena8 Endothelial™
biochip (channel volume: 2.69 µL) (Cellix Ltd, Dublin, Ireland) was used. The biochips were coated
with a 0.5 mm layer of 10 µg/mL fibronectin solution, incubated for 1 h and washed with PBS in a
humidified environment. Then, 1.5 × 106 of hCMEC/D3 cells were seeded in each channel and left to
adhere for 2 h. The biochips were then plugged in to a microfluidic pump (Cellix Ltd., Dublin, Ireland),
set up on perfusion mode with a 10 mL/h and 2.5 dyn/cm2 volumetric rate and kept in an incubator
at 37 ◦C, 5% CO2. The adhesion assay was conducted after 24–48 h and TNF-α (25 pg/mL) was added
to the circulating medium. The biochip was connected to a Zeiss Axiovert 200M inverted live cell (time
lapse) microscope at 37 ◦C, 5% CO2 and 1 × 106 cells/mL green fluorescently tagged NSCLC cells
were perfused onto the hCMEC/D3 monolayer at 2.5 dyn/cm2. The flow rate was controlled via a
Mirus Evo nanopump (Cellix Ltd., Dublin, Ireland) and Vena Flux Assay software. Live cell images
were taken once every 10 min over 2 h to monitor cancer cell adhesion on the brain endothelial cell
monolayer. Volocity software (V5.4, PerkinElmer, Waltham, MA, USA) was used to generate movie
sequences. The experiment was repeated three independent times in triplicate.
4.10. Immunohistochemistry (IHC)
IHC was conducted on paraffin embedded, formalin fixed tissue sections (FFPE) of human
lung to brain metastatic cancer biopsies using antibodies to CD15s and CD62E. Briefly, 4 µm thick
FFPE sections were dewaxed in Xylene, rehydrated in 100%, 95%, 70% ethanol and deionized water
respectively followed by 40 min of heat-induced epitope retrieval with citrate buffer (6.0 pH) at 95 ◦C
and incubated with 3% hydrogen peroxide in methanol for 30 min to block endogenous peroxidase
and biotin activity. Tissues were then blocked with 3% horse serum for 30 min and probed with
primary antibodies for 1 h at room temperature. The Elite Vector Stain ABC system (Vector Labs,
Burlingame, CA, USA) was employed as a detection system and DAB stain (Vector Labs, Burlingame,
CA, USA) was used as a chromogen. Meyer’s haematoxylin (Sigma-Aldrich, Gillingham, UK) was
used as a counterstain. Mouse IgM and IgG isotopes were used instead of primary antibodies in
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negative controls. Tissue sections were examined using a bright field automated microscope Ariol
(Leica) for qualitative image analysis.
4.11. Confocal Microscopy
ICC images were obtained using the X63 oil immersion objective of a Zeiss LSM 510 Meta Axioskop
2 confocal microscope using lasers with excitation wave lengths of 405 nm (blue), 488 nm (green),
568 nm (red) and 674 nm (purple), with diode, argon and HeNe1 lasers, respectively. Identical settings
were used to image negative controls in which primary antibody was used by non-specific Isotype.
4.12. Statistical Analysis
All experiments were conducted independently three times and the data expressed as ±SE.
One-way ANOVA followed by Tukey’s multiple comparison post-hoc tests using Graph Pad Prism
6 software (version 6.1, UK) was used for statistical analysis.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/7/1474/s1.
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